PortalPublikationenIndependent contribution of polygenic risk for schizophrenia...

Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene × environment moderation and mediation

Standard

Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene × environment moderation and mediation. / Elkrief, Laurent; Lin, Bochao; Marchi, Mattia; Afzali, Mohammad H; Banaschewski, Tobias; Bokde, Arun L W; Quinlan, Erin Burke; Desrivières, Sylvane; Flor, Herta; Garavan, Hugh; Gowland, Penny; Heinz, Andreas; Ittermann, Bernd; Martinot, Jean-Luc; Martinot, Marie-Laure Paillère; Nees, Frauke; Orfanos, Dimitri Papadopoulos; Paus, Tomáš; Poustka, Luise; Hohmann, Sarah; Fröhner, Juliane H; Smolka, Michael N; Walter, Henrik; Whelan, Robert; Schumann, Gunter; Luykx, Jurjen; Boks, Marco P; Conrod, Patricia J; IMAGEN Consortium.

in: PSYCHOL MED, Jahrgang 53, Nr. 5, 04.2023, S. 1759-1769.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Elkrief, L, Lin, B, Marchi, M, Afzali, MH, Banaschewski, T, Bokde, ALW, Quinlan, EB, Desrivières, S, Flor, H, Garavan, H, Gowland, P, Heinz, A, Ittermann, B, Martinot, J-L, Martinot, M-LP, Nees, F, Orfanos, DP, Paus, T, Poustka, L, Hohmann, S, Fröhner, JH, Smolka, MN, Walter, H, Whelan, R, Schumann, G, Luykx, J, Boks, MP, Conrod, PJ & IMAGEN Consortium 2023, 'Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene × environment moderation and mediation', PSYCHOL MED, Jg. 53, Nr. 5, S. 1759-1769. https://doi.org/10.1017/S0033291721003378

APA

Elkrief, L., Lin, B., Marchi, M., Afzali, M. H., Banaschewski, T., Bokde, A. L. W., Quinlan, E. B., Desrivières, S., Flor, H., Garavan, H., Gowland, P., Heinz, A., Ittermann, B., Martinot, J-L., Martinot, M-L. P., Nees, F., Orfanos, D. P., Paus, T., Poustka, L., ... IMAGEN Consortium (2023). Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene × environment moderation and mediation. PSYCHOL MED, 53(5), 1759-1769. https://doi.org/10.1017/S0033291721003378

Vancouver

Elkrief L, Lin B, Marchi M, Afzali MH, Banaschewski T, Bokde ALW et al. Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene × environment moderation and mediation. PSYCHOL MED. 2023 Apr;53(5):1759-1769. https://doi.org/10.1017/S0033291721003378

Bibtex

@article{2ad90048ff714d0b99d96ab7f3efaa1d,
title = "Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene × environment moderation and mediation",
abstract = "BACKGROUND: It has not yet been determined if the commonly reported cannabis-psychosis association is limited to individuals with pre-existing genetic risk for psychotic disorders.METHODS: We examined whether the relationship between polygenic risk score for schizophrenia (PRS-Sz) and psychotic-like experiences (PLEs), as measured by the Community Assessment of Psychic Experiences-42 (CAPE-42) questionnaire, is mediated or moderated by lifetime cannabis use at 16 years of age in 1740 of the individuals of the European IMAGEN cohort. Secondary analysis examined the relationships between lifetime cannabis use, PRS-Sz and the various sub-scales of the CAPE-42. Sensitivity analyses including covariates, including a PRS for cannabis use, were conducted and results were replicated using data from 1223 individuals in the Dutch Utrecht cannabis cohort.RESULTS: PRS-Sz significantly predicted cannabis use (p = 0.027) and PLE (p = 0.004) in the IMAGEN cohort. In the full model, considering PRS-Sz and covariates, cannabis use was also significantly associated with PLE in IMAGEN (p = 0.007). Results remained consistent in the Utrecht cohort and through sensitivity analyses. Nevertheless, there was no evidence of a mediation or moderation effects.CONCLUSIONS: These results suggest that cannabis use remains a risk factor for PLEs, over and above genetic vulnerability for schizophrenia. This research does not support the notion that the cannabis-psychosis link is limited to individuals who are genetically predisposed to psychosis and suggests a need for research focusing on cannabis-related processes in psychosis that cannot be explained by genetic vulnerability.",
keywords = "Humans, Young Adult, Adult, Schizophrenia/epidemiology, Cannabis/adverse effects, Hallucinogens, Psychotic Disorders/epidemiology, Cannabinoid Receptor Agonists",
author = "Laurent Elkrief and Bochao Lin and Mattia Marchi and Afzali, {Mohammad H} and Tobias Banaschewski and Bokde, {Arun L W} and Quinlan, {Erin Burke} and Sylvane Desrivi{\`e}res and Herta Flor and Hugh Garavan and Penny Gowland and Andreas Heinz and Bernd Ittermann and Jean-Luc Martinot and Martinot, {Marie-Laure Paill{\`e}re} and Frauke Nees and Orfanos, {Dimitri Papadopoulos} and Tom{\'a}{\v s} Paus and Luise Poustka and Sarah Hohmann and Fr{\"o}hner, {Juliane H} and Smolka, {Michael N} and Henrik Walter and Robert Whelan and Gunter Schumann and Jurjen Luykx and Boks, {Marco P} and Conrod, {Patricia J} and {IMAGEN Consortium}",
year = "2023",
month = apr,
doi = "10.1017/S0033291721003378",
language = "English",
volume = "53",
pages = "1759--1769",
journal = "PSYCHOL MED",
issn = "0033-2917",
publisher = "Cambridge University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene × environment moderation and mediation

AU - Elkrief, Laurent

AU - Lin, Bochao

AU - Marchi, Mattia

AU - Afzali, Mohammad H

AU - Banaschewski, Tobias

AU - Bokde, Arun L W

AU - Quinlan, Erin Burke

AU - Desrivières, Sylvane

AU - Flor, Herta

AU - Garavan, Hugh

AU - Gowland, Penny

AU - Heinz, Andreas

AU - Ittermann, Bernd

AU - Martinot, Jean-Luc

AU - Martinot, Marie-Laure Paillère

AU - Nees, Frauke

AU - Orfanos, Dimitri Papadopoulos

AU - Paus, Tomáš

AU - Poustka, Luise

AU - Hohmann, Sarah

AU - Fröhner, Juliane H

AU - Smolka, Michael N

AU - Walter, Henrik

AU - Whelan, Robert

AU - Schumann, Gunter

AU - Luykx, Jurjen

AU - Boks, Marco P

AU - Conrod, Patricia J

AU - IMAGEN Consortium

PY - 2023/4

Y1 - 2023/4

N2 - BACKGROUND: It has not yet been determined if the commonly reported cannabis-psychosis association is limited to individuals with pre-existing genetic risk for psychotic disorders.METHODS: We examined whether the relationship between polygenic risk score for schizophrenia (PRS-Sz) and psychotic-like experiences (PLEs), as measured by the Community Assessment of Psychic Experiences-42 (CAPE-42) questionnaire, is mediated or moderated by lifetime cannabis use at 16 years of age in 1740 of the individuals of the European IMAGEN cohort. Secondary analysis examined the relationships between lifetime cannabis use, PRS-Sz and the various sub-scales of the CAPE-42. Sensitivity analyses including covariates, including a PRS for cannabis use, were conducted and results were replicated using data from 1223 individuals in the Dutch Utrecht cannabis cohort.RESULTS: PRS-Sz significantly predicted cannabis use (p = 0.027) and PLE (p = 0.004) in the IMAGEN cohort. In the full model, considering PRS-Sz and covariates, cannabis use was also significantly associated with PLE in IMAGEN (p = 0.007). Results remained consistent in the Utrecht cohort and through sensitivity analyses. Nevertheless, there was no evidence of a mediation or moderation effects.CONCLUSIONS: These results suggest that cannabis use remains a risk factor for PLEs, over and above genetic vulnerability for schizophrenia. This research does not support the notion that the cannabis-psychosis link is limited to individuals who are genetically predisposed to psychosis and suggests a need for research focusing on cannabis-related processes in psychosis that cannot be explained by genetic vulnerability.

AB - BACKGROUND: It has not yet been determined if the commonly reported cannabis-psychosis association is limited to individuals with pre-existing genetic risk for psychotic disorders.METHODS: We examined whether the relationship between polygenic risk score for schizophrenia (PRS-Sz) and psychotic-like experiences (PLEs), as measured by the Community Assessment of Psychic Experiences-42 (CAPE-42) questionnaire, is mediated or moderated by lifetime cannabis use at 16 years of age in 1740 of the individuals of the European IMAGEN cohort. Secondary analysis examined the relationships between lifetime cannabis use, PRS-Sz and the various sub-scales of the CAPE-42. Sensitivity analyses including covariates, including a PRS for cannabis use, were conducted and results were replicated using data from 1223 individuals in the Dutch Utrecht cannabis cohort.RESULTS: PRS-Sz significantly predicted cannabis use (p = 0.027) and PLE (p = 0.004) in the IMAGEN cohort. In the full model, considering PRS-Sz and covariates, cannabis use was also significantly associated with PLE in IMAGEN (p = 0.007). Results remained consistent in the Utrecht cohort and through sensitivity analyses. Nevertheless, there was no evidence of a mediation or moderation effects.CONCLUSIONS: These results suggest that cannabis use remains a risk factor for PLEs, over and above genetic vulnerability for schizophrenia. This research does not support the notion that the cannabis-psychosis link is limited to individuals who are genetically predisposed to psychosis and suggests a need for research focusing on cannabis-related processes in psychosis that cannot be explained by genetic vulnerability.

KW - Humans

KW - Young Adult

KW - Adult

KW - Schizophrenia/epidemiology

KW - Cannabis/adverse effects

KW - Hallucinogens

KW - Psychotic Disorders/epidemiology

KW - Cannabinoid Receptor Agonists

U2 - 10.1017/S0033291721003378

DO - 10.1017/S0033291721003378

M3 - SCORING: Journal article

C2 - 37310336

VL - 53

SP - 1759

EP - 1769

JO - PSYCHOL MED

JF - PSYCHOL MED

SN - 0033-2917

IS - 5

ER -